A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

Clinical trial NCT03321630 · COMPLETED

Trial details

NCT number

NCT03321630

Sponsor

NYU Langone Health

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2017-10-24

Primary completion

2023-03-10

Enrollment

24

View on ClinicalTrials.gov